mitoxantrone has been researched along with Alopecia in 28 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Alopecia: Absence of hair from areas where it is normally present.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)." | 9.09 | Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. ( Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001) |
| "A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 patients with relapsing, secondary multiple sclerosis." | 9.09 | A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. ( Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001) |
| "To evaluate the efficiency of mitoxantrone in multiple sclerosis." | 9.08 | Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. ( Berry, I; Brochet, B; Cabanis, E; Clanet, M; Confavreux, C; Edan, G; Froment, JC; Gandon, JM; Iba-Zizen, MT; Lai, HM; Lubetzki, C; Lyon-Caen, O; Miller, D; Moseley, I; Rolland, Y; Sabouraud, O, 1997) |
| "In an attempt to examine the possibility of decreased toxicity in patients with advanced breast cancer who had not previously received chemotherapy, 33 women were given combination chemotherapy consisting of mitomycin C (10 mg/m2) every 6 weeks and mitoxantrone (6 mg/m2) every 3 weeks." | 9.06 | Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. ( Begin, L; Margolese, R; Panasci, L; Pollak, M; Reinke, A; Shenouda, G, 1990) |
| "To exploit possible different non-cross-resistant mechanisms of cytotoxicity, 25 patients with advanced breast cancer were given combination chemotherapy consisting of iv mitoxantrone (7 mg/m2) and doxorubicin (30 mg/m2) every 3-4 weeks." | 9.06 | Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer. ( Ford, JM; Leclerc, Y; Margolese, R; Panasci, L, 1987) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 9.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "Eighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m2 day 1, followed by 5-fluorouracil 375 mg/m2 day 1-5, and high-dose leucovorin 500 mg/m2 day 1-5 given every 28 days." | 7.69 | Mitoxantrone, 5-FU, and leucovorin in breast cancer. ( Honig, SF; Swain, SM, 1994) |
| "Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy." | 7.67 | Mitoxantrone in refractory acute leukemia in children: a phase I study. ( Dukart, G; Mulne, AF; Schoch, I; Starling, KA; Vats, TS, 1985) |
| "1 years) and 1 male (71 years) with histologically verified metastasizing breast cancer were submitted to mitoxantrone therapy." | 7.67 | [Mitoxantrone in the primary treatment of metastasizing breast cancer]. ( Dittrich, C; Dudczak, R; Lenzhofer, R; Moser, K; Pirker, P; Rainer, H; Schuster, R, 1984) |
| "Two phase II trials of mitoxantrone (Novantrone; dihydroxyanthracenedione) in refractory malignant lymphoma have been conducted." | 7.67 | Mitoxantrone in malignant lymphoma. ( Bryan, S; Case, D; Dukart, G; Gams, RA; Jones, S; Stein, R; Weiss, A, 1985) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 7.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed." | 7.67 | [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984) |
| "Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone." | 7.67 | Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Heidemann, E; Ho, AD; Meyer, P; Mjaaland, I; Seither, E, 1985) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 7.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 6.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "Leukopenia is similar with the three drugs." | 6.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| "Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin." | 5.27 | An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984) |
| "Mitoxantrone was well tolerated with myelosuppression as the dose-limiting toxicity." | 5.27 | Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. ( Coleman, R; Cornbleet, M; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, R; Smith, I; Smyth, J; Stuart-Harris, R; van Oosterom, A, 1985) |
| "The applicability and efficacy of a scalp cooling system were studied in 105 breast cancer patients receiving four cycles of adjuvant chemotherapy with mitoxantrone + cyclophosphamide (NC chemotherapy)." | 5.10 | Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy. ( Camerlo, J; d'Ingrado, MP; Evans, K; Genre, D; Macquart-Moulin, G; Maraninchi, D; Protière, C; Viens, P, 2002) |
| "A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 patients with relapsing, secondary multiple sclerosis." | 5.09 | A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. ( Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001) |
| "To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)." | 5.09 | Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. ( Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001) |
| "To evaluate the efficiency of mitoxantrone in multiple sclerosis." | 5.08 | Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. ( Berry, I; Brochet, B; Cabanis, E; Clanet, M; Confavreux, C; Edan, G; Froment, JC; Gandon, JM; Iba-Zizen, MT; Lai, HM; Lubetzki, C; Lyon-Caen, O; Miller, D; Moseley, I; Rolland, Y; Sabouraud, O, 1997) |
| "To exploit possible different non-cross-resistant mechanisms of cytotoxicity, 25 patients with advanced breast cancer were given combination chemotherapy consisting of iv mitoxantrone (7 mg/m2) and doxorubicin (30 mg/m2) every 3-4 weeks." | 5.06 | Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer. ( Ford, JM; Leclerc, Y; Margolese, R; Panasci, L, 1987) |
| "In an attempt to examine the possibility of decreased toxicity in patients with advanced breast cancer who had not previously received chemotherapy, 33 women were given combination chemotherapy consisting of mitomycin C (10 mg/m2) every 6 weeks and mitoxantrone (6 mg/m2) every 3 weeks." | 5.06 | Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. ( Begin, L; Margolese, R; Panasci, L; Pollak, M; Reinke, A; Shenouda, G, 1990) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 5.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "Eighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m2 day 1, followed by 5-fluorouracil 375 mg/m2 day 1-5, and high-dose leucovorin 500 mg/m2 day 1-5 given every 28 days." | 3.69 | Mitoxantrone, 5-FU, and leucovorin in breast cancer. ( Honig, SF; Swain, SM, 1994) |
| "1 years) and 1 male (71 years) with histologically verified metastasizing breast cancer were submitted to mitoxantrone therapy." | 3.67 | [Mitoxantrone in the primary treatment of metastasizing breast cancer]. ( Dittrich, C; Dudczak, R; Lenzhofer, R; Moser, K; Pirker, P; Rainer, H; Schuster, R, 1984) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 3.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone." | 3.67 | Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Heidemann, E; Ho, AD; Meyer, P; Mjaaland, I; Seither, E, 1985) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 3.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed." | 3.67 | [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984) |
| "Two phase II trials of mitoxantrone (Novantrone; dihydroxyanthracenedione) in refractory malignant lymphoma have been conducted." | 3.67 | Mitoxantrone in malignant lymphoma. ( Bryan, S; Case, D; Dukart, G; Gams, RA; Jones, S; Stein, R; Weiss, A, 1985) |
| "Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy." | 3.67 | Mitoxantrone in refractory acute leukemia in children: a phase I study. ( Dukart, G; Mulne, AF; Schoch, I; Starling, KA; Vats, TS, 1985) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 2.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "132 patients with advanced recurrent breast cancer were treated with four courses of mitozantrone 14 mg/m2 intravenously every 3 weeks (9 weeks)." | 2.67 | Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. ( Cantwell, BM; Carmichael, J; Dawes, P; Evans, RG; Farndon, J; Ghani, S; Harris, AL; Wilson, R, 1990) |
| "Leukopenia is similar with the three drugs." | 2.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| "To date, all available therapies for prostate cancer are plagued by adverse effects." | 2.41 | Complications of chemotherapy for prostate cancer. ( Beer, TM; Bubalo, JS, 2001) |
| "Mitoxantrone was well tolerated with myelosuppression as the dose-limiting toxicity." | 1.27 | Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. ( Coleman, R; Cornbleet, M; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, R; Smith, I; Smyth, J; Stuart-Harris, R; van Oosterom, A, 1985) |
| "Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin." | 1.27 | An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (50.00) | 18.7374 |
| 1990's | 8 (28.57) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhong, LY | 1 |
| Li, QH | 1 |
| Huang, ZL | 1 |
| Lin, W | 1 |
| Lu, ZS | 1 |
| Weng, JY | 1 |
| Wu, SJ | 1 |
| Du, X | 1 |
| Protière, C | 1 |
| Evans, K | 1 |
| Camerlo, J | 1 |
| d'Ingrado, MP | 1 |
| Macquart-Moulin, G | 1 |
| Viens, P | 1 |
| Maraninchi, D | 1 |
| Genre, D | 1 |
| Lenzhofer, R | 1 |
| Rainer, H | 2 |
| Schuster, R | 1 |
| Pirker, P | 1 |
| Dudczak, R | 1 |
| Dittrich, C | 1 |
| Moser, K | 1 |
| De Jager, R | 1 |
| Cappelaere, P | 2 |
| Armand, JP | 2 |
| Keiling, R | 2 |
| Fargeot, P | 1 |
| Bastit, P | 1 |
| van Glabbeke, M | 1 |
| Renard, J | 1 |
| Earl, H | 1 |
| Rubens, R | 2 |
| Tominaga, T | 1 |
| Kitamura, M | 1 |
| Hayashi, K | 1 |
| Takahashi, I | 1 |
| Kosaki, G | 1 |
| Arlin, ZA | 1 |
| Friedland, ML | 1 |
| Atamer, MA | 1 |
| Swain, SM | 1 |
| Honig, SF | 1 |
| Edan, G | 1 |
| Miller, D | 1 |
| Clanet, M | 1 |
| Confavreux, C | 1 |
| Lyon-Caen, O | 1 |
| Lubetzki, C | 1 |
| Brochet, B | 1 |
| Berry, I | 1 |
| Rolland, Y | 1 |
| Froment, JC | 1 |
| Cabanis, E | 1 |
| Iba-Zizen, MT | 1 |
| Gandon, JM | 1 |
| Lai, HM | 1 |
| Moseley, I | 1 |
| Sabouraud, O | 1 |
| Kakolyris, S | 2 |
| Kourousis, C | 1 |
| Koukourakis, M | 1 |
| Androulakis, N | 1 |
| Vamvakas, L | 1 |
| Agelaki, S | 2 |
| Hatzidaki, D | 1 |
| Samonis, G | 1 |
| Tsiftsis, D | 1 |
| Georgoulias, V | 2 |
| Alexopoulos, A | 1 |
| Kouroussis, C | 1 |
| Malamos, N | 1 |
| Kalbakis, K | 1 |
| Kosmas, C | 1 |
| Mavroudis, D | 1 |
| Vlachonicolis, J | 1 |
| Sarra, E | 1 |
| Rigatos, G | 1 |
| Beer, TM | 1 |
| Bubalo, JS | 1 |
| van de Wyngaert, FA | 1 |
| Beguin, C | 1 |
| D'Hooghe, MB | 1 |
| Dooms, G | 1 |
| Lissoir, F | 1 |
| Carton, H | 1 |
| Sindic, CJ | 1 |
| Economopoulos, T | 1 |
| Dimopoulos, MA | 1 |
| Mellou, S | 1 |
| Pavlidis, N | 1 |
| Samantas, E | 1 |
| Nicolaides, C | 1 |
| Tsatalas, C | 1 |
| Papadopoulos, A | 1 |
| Papageogriou, E | 1 |
| Papasavvas, P | 1 |
| Fountzilas, G | 1 |
| Delozier, T | 1 |
| Vernhes, JC | 1 |
| Brun, B | 1 |
| Nasr, E | 1 |
| Randria, G | 1 |
| Feuilhade, F | 1 |
| Gimonet, JF | 1 |
| Le Bourgeois, JP | 1 |
| Gherlinzoni, F | 1 |
| Guglielmi, C | 1 |
| Mazza, P | 1 |
| Amadori, S | 1 |
| Mandelli, F | 1 |
| Tura, S | 1 |
| Harris, AL | 1 |
| Cantwell, BM | 1 |
| Carmichael, J | 1 |
| Wilson, R | 1 |
| Farndon, J | 1 |
| Dawes, P | 1 |
| Ghani, S | 1 |
| Evans, RG | 1 |
| Panasci, L | 2 |
| Shenouda, G | 1 |
| Begin, L | 1 |
| Pollak, M | 1 |
| Reinke, A | 1 |
| Margolese, R | 2 |
| Martoni, A | 1 |
| Rani, P | 1 |
| Ercolino, L | 1 |
| Canova, N | 1 |
| Pannuti, F | 1 |
| Ford, JM | 1 |
| Leclerc, Y | 1 |
| Meyer, P | 1 |
| Ho, AD | 1 |
| Ehninger, G | 1 |
| Mjaaland, I | 1 |
| Heidemann, E | 1 |
| Seither, E | 1 |
| Cowan, JD | 1 |
| Osborne, CK | 1 |
| Neidhart, JA | 1 |
| Von Hoff, DD | 1 |
| Constanzi, JJ | 1 |
| Vaughn, CB | 1 |
| Bennett, JM | 1 |
| Byrne, P | 1 |
| Desai, A | 1 |
| White, C | 1 |
| DeConti, R | 1 |
| Vogel, C | 1 |
| Krementz, E | 1 |
| Muggia, F | 1 |
| Doroshow, J | 1 |
| Plotkin, D | 1 |
| Mouridsen, HT | 2 |
| Andersson, M | 1 |
| Pedersen, L | 1 |
| Cornbleet, M | 1 |
| Stuart-Harris, R | 1 |
| Smith, I | 1 |
| Coleman, R | 1 |
| McDonald, M | 1 |
| van Oosterom, A | 1 |
| Smyth, J | 1 |
| Metz, R | 1 |
| Delgado, M | 1 |
| Prevot, G | 1 |
| Misset, JL | 1 |
| Grimbert, J | 1 |
| Mathe, G | 1 |
| Gams, RA | 1 |
| Bryan, S | 1 |
| Dukart, G | 2 |
| Weiss, A | 1 |
| Case, D | 1 |
| Jones, S | 1 |
| Stein, R | 1 |
| Starling, KA | 1 |
| Mulne, AF | 1 |
| Vats, TS | 1 |
| Schoch, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma[NCT03151044] | Phase 3 | 408 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mitoxantrone and Alopecia
| Article | Year |
|---|---|
Complications of chemotherapy for prostate cancer.
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Docetaxel; Ga | 2001 |
[Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature].
Topics: Alopecia; Doxorubicin; Epirubicin; Heart; Humans; Leukopenia; Mitoxantrone; Nausea; Randomized Contr | 1991 |
13 trials available for mitoxantrone and Alopecia
| Article | Year |
|---|---|
Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Agranulocytosis; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cytara | 2009 |
Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 2002 |
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Topics: Adjuvants, Immunologic; Adult; Alopecia; Amenorrhea; Drug Therapy, Combination; Female; Follow-Up St | 1997 |
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplas | 1999 |
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast | 2001 |
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
Topics: Adult; Alopecia; Contrast Media; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans; | 2001 |
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; | 1990 |
Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer.
Topics: Adult; Aged; Alopecia; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Administration | 1990 |
Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia.
Topics: Alkylating Agents; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diges | 1990 |
Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1987 |
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Topics: Adult; Aged; Alopecia; Anthracenes; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinica | 1985 |
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1985 |
13 other studies available for mitoxantrone and Alopecia
| Article | Year |
|---|---|
[Mitoxantrone in the primary treatment of metastasizing breast cancer].
Topics: Aged; Alopecia; Anthraquinones; Brain Neoplasms; Breast Neoplasms; Drug Tolerance; Electrocardiograp | 1984 |
An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
Topics: Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Carcinom | 1984 |
[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Mi | 1984 |
Selective alopecia with mitoxantrone.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Female; Hair Color; Humans; Male; Mito | 1984 |
Mitoxantrone, 5-FU, and leucovorin in breast cancer.
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Adm | 1994 |
[Pilot study of chemotherapy with mitoxantrone, ifosfamide, 5-fluorouracil in metastatic cancers of the breast. Preliminary study].
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cause of Death; Fe | 1991 |
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1988 |
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow | 1985 |
Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1986 |
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Drug Ev | 1985 |
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph | 1985 |
Mitoxantrone in malignant lymphoma.
Topics: Alopecia; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Humans; Leukocyte Count; Lymphoma; | 1985 |
Mitoxantrone in refractory acute leukemia in children: a phase I study.
Topics: Acute Disease; Adolescent; Alopecia; Anthraquinones; Antineoplastic Agents; Child; Child, Preschool; | 1985 |